Cervical cancer associated with human papillomavirus (HPV) affects approximately 1000 Australian women each year, causing about 300 deaths.1 The newly licensed HPV vaccines Gardasil (CSL Limited), a quadrivalent vaccine (4vHPV), and Cervarix (GlaxoSmithKline Vaccines), a bivalent vaccine (2vHPV), induce protection against the two most common strains of HPV, which cause 70% of all cervi
- Careers centre
- MJA Open
- Job Search
Mass psychogenic response to human papillomavirus vaccination
Jim P Buttery, Simon Madin, Nigel W Crawford, Sonja Elia, Sophie La Vincente, Sarah Hanieh, Lindsay Smith and Bruce Bolam
Med J Aust 2008; 189 (5): 261-262.
Jim P Buttery, MB BS, MSc, FRACP, Infectious Diseases Physician1,2,3
Simon Madin, MB BS, Immunisation Manager4
Nigel W Crawford, MB BS, FRACP, MPH, Paediatrician1,2,3
Sonja Elia, RN, Nursing Coordinator1,3,5
Sophie La Vincente, MSc, MAE Student1,5
Sarah Hanieh, MB BS, Infectious Diseases Fellow2,3
Lindsay Smith, MB BS, FRACP, Neurologist6
Bruce Bolam, MB BS, MPH, Public Health Trainee4
3 Infectious Diseases Unit and Immunisation Service, Department of General Medicine, Royal Children’s Hospital, Melbourne, VIC.
5 National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT.
Australian Institute of Health and Welfare. Cancer in Australia 2001. Canberra: AIHW, 2004. (AIHW Cat. No. CAN 23; Cancer series No. 28.)
Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-1255.
Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369: 1693-1702.
Clements CJ. Mass psychogenic illness after vaccination. Drug Saf 2003; 26: 599-604.
Tanne JH. Questions over human papillomavirus vaccine in the US and Australia. BMJ 2007; 334: 1182-1183.
Clements CJ. Gardasil and mass psychogenic illness. Aust N Z J Public Health 2007; 31: 387.
The full contents of this page are only available to subscribers.
Log in to keep reading
* Required information